PTCT earnings call for the period ending September 30, 2019.
News & Analysis: PTC Therapeutics
The company more than doubled its cash balance from the end of June with two fundraising transactions.
The business is raising cash through two offerings: one of debt and one of common stock.
The company announced the pricing of a share offering announced the day before.
The company's development-stage SMA treatment was supposed to knock out the market leader, but now it may be the one at risk of an upset.
The company's making an acquisition to bulk up its pipeline of clinical-stage drugs.
Welcome to biotech investing.
Investors value a new round of data for PTC's spinal muscular atrophy drug.
Investors are unimpressed with data -- so far -- for the biotech's spinal muscular atrophy drug RG7916.
Investors are clinging to hopes that yesterday's advisory committee meeting wasn't as bad as it seemed.
Recently released briefing documents suggest the company's previously rejected new drug application still isn't ready.